| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
1,250,000,000 |
| Market
Cap: |
80.88(B) |
| Last
Volume: |
7,412,694 |
Avg
Vol: |
8,704,124 |
| 52
Week Range: |
$63.43 - $87.29 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 500 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 259 |
| Guru Rank Value : 4.6 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s primary areas of focus include viral diseases, inflammatory diseases and oncology. Co.'s products include: Biktarvy® for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), for the treatment of Coronavirus Disease 2019 requiring hospitalization; Epclusa® for the treatment of chronic hepatitis C virus infection; Vemlidy® for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease; Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
2,000 |
25,472 |
38,458 |
80,792 |
| Total Sell Value |
$145,920 |
$2,022,270 |
$3,052,046 |
$6,445,296 |
| Total People Sold |
1 |
3 |
3 |
4 |
| Total Sell Transactions |
1 |
5 |
9 |
14 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Carter Paul Rutherford |
EVP Commercial Ops |
• • – |
2016-05-31 |
4 |
AS |
$86.85 |
$4,958,600 |
D/D |
(57,092) |
61,122 |
|
- |
|
| Carter Paul Rutherford |
EVP Commercial Ops |
• • – |
2016-05-31 |
4 |
OE |
$24.30 |
$1,934,021 |
D/D |
57,092 |
118,214 |
|
- |
|
| Young Kevin |
Chief Operating OfficerOfficer |
• – – |
2016-05-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,126 |
|
- |
|
| Lofton Kevin E |
Director |
• • – |
2016-05-21 |
4 |
A |
$0.00 |
$0 |
I/I |
3,500 |
3,500 |
|
- |
|
| Wilson Gayle E |
Director |
• • – |
2016-05-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,466 |
105,339 |
|
- |
|
| Hills Carla A |
Director |
• • – |
2016-05-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,466 |
39,285 |
|
- |
|
| Wold Olsen Per |
Director |
• • – |
2016-05-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,466 |
91,543 |
|
- |
|
| Cogan John Francis |
Director |
• • – |
2016-05-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,466 |
45,775 |
|
- |
|
| Whitley Richard James |
Director |
• • – |
2016-05-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,466 |
25,135 |
|
- |
|
| Madigan John W |
Director |
• • – |
2016-05-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,466 |
16,761 |
|
- |
|
| Davignon Etienne |
Director |
• • – |
2016-05-06 |
4 |
D |
$84.68 |
$35,481 |
D/D |
(419) |
838,652 |
|
- |
|
| Davignon Etienne |
Director |
• • – |
2016-05-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,466 |
839,071 |
|
- |
|
| Carter Paul Rutherford |
EVP Commercial Ops |
• • – |
2016-05-02 |
4 |
AS |
$88.72 |
$177,448 |
D/D |
(2,000) |
61,122 |
|
- |
|
| Carter Paul Rutherford |
EVP Commercial Ops |
• • – |
2016-05-02 |
4 |
OE |
$24.91 |
$78,255 |
D/D |
2,000 |
63,122 |
|
- |
|
| Milligan John F |
President and CEO |
• • – |
2016-05-02 |
4 |
AS |
$87.27 |
$9,823,954 |
D/D |
(112,000) |
1,058,963 |
|
- |
|
| Milligan John F |
President and CEO |
• • – |
2016-05-02 |
4 |
OE |
$16.40 |
$1,836,240 |
D/D |
112,000 |
1,170,963 |
|
- |
|
| Martin John C |
Executive Chairman |
• • – |
2016-05-02 |
4 |
AS |
$87.40 |
$8,781,694 |
D/D |
(100,000) |
4,019,727 |
|
- |
|
| Martin John C |
Executive Chairman |
• • – |
2016-05-02 |
4 |
OE |
$16.40 |
$1,639,500 |
D/D |
100,000 |
4,119,727 |
|
- |
|
| Alton Gregg H |
EVP, Corp & Med Affairs |
• • – |
2016-04-19 |
4 |
AS |
$100.00 |
$4,000,574 |
D/D |
(40,000) |
137,964 |
|
- |
|
| Alton Gregg H |
EVP, Corp & Med Affairs |
• • – |
2016-04-19 |
4 |
OE |
$26.99 |
$968,239 |
D/D |
35,874 |
177,964 |
|
- |
|
| Milligan John F |
President and CEO |
• • – |
2016-04-04 |
4 |
AS |
$94.54 |
$10,593,904 |
D/D |
(112,000) |
1,058,963 |
|
- |
|
| Milligan John F |
President and CEO |
• • – |
2016-04-04 |
4 |
OE |
$16.40 |
$1,836,240 |
D/D |
112,000 |
1,170,963 |
|
- |
|
| Martin John C |
Executive Chairman |
• • – |
2016-04-01 |
4 |
AS |
$91.50 |
$9,323,507 |
D/D |
(100,000) |
4,019,727 |
|
- |
|
| Martin John C |
Executive Chairman |
• • – |
2016-04-01 |
4 |
OE |
$16.40 |
$1,639,500 |
D/D |
100,000 |
4,119,727 |
|
- |
|
| Alton Gregg H |
EVP, Corp & Med Affairs |
• • – |
2016-04-01 |
4 |
S |
$91.23 |
$456,158 |
D/D |
(5,000) |
142,090 |
|
- |
|
2499 Records found
|
|
Page 29 of 100 |
|
|
0.85 (1.33%) 
